AMGN Amgen
- 277.370
- +3.430+1.25%
- 277.850
- +0.480+0.17%
Amgen News
What's Going On With CytomX Stock?
CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares are racing higher Wednesday. The company said it will report first-quarter results and provide an initial CX-904 Phase 1a dose escalation update on May 8
CytomX Surges on Upcoming Data for Amgen-partnered Cancer Drug
Economic schedule for 2nd (Thu) ★ Apple financial results etc.
<9983><9977>5/2 (Thursday) Tomobiki, Moon Age 23.4 “5 wins and 5 losses” (taking the Nikkei Average's yin and yang stars in the past 10 years) [Domestic] □ Bank of Japan Monetary Policy Meeting Minutes (3/18/19, 8:50) □ April Monetary Base (8:50) □ April Consumption Trend Survey (14:00) □ Fast Announces April Domestic UNIQLO Sales Trend Bulletin (circa 15:00) [Domestic Companies] ○Aoki Super [TSE S]: Delisting [Overseas] China Market ★ Closed (Labor Day)
Amgen Investors Await Weight-loss Drug Data
Express News | Amgen Highlights New Copd, Asthma and Vasculitis Research at ATS 2024
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab biosim
Dow Drops 150 Points On Losses For Caterpillar, Amgen Shares
This article was automatically generated by MarketWatch using technology from Automated Insights. The Dow Jones Industrial Average is falling Tuesday morning with shares of Caterpillar and Amgen deli
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Health care stocks were mixed premarket Tuesday, with the iShares Biotechnology ETF (IBB) down 0.3% and Health Care Select Sector SPDR Fund (XLV) up 0.3%. Eli Lilly (LLY) shares were up over 5% after
Amgen (AMGN) Gets a Buy From Truist Financial
Sandoz Says Anticipated Launch Strengthens Biosimilar Portfolio, Advances Growth Strategy
Sandoz Says Anticipated Launch Strengthens Biosimilar Portfolio, Advances Growth Strategy
Sandoz: Settlement Clears Path for Launch of Jubbonti and Wyost on May 31, 2025
Sandoz: Settlement Clears Path for Launch of Jubbonti and Wyost on May 31, 2025
Express News | Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation Related to Its US Denosumab Biosimilars
What's in the Cards for Amgen (AMGN) This Earnings Season?
Insights Into Amgen (AMGN) Q1: Wall Street Projections for Key Metrics
AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., April 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the
J&J, Roche, AstraZeneca Poised to Have Highest Orphan Drug Sales by End of Decade
Amgen's Blincyto Data Send Cullinan Higher
Cullinan Therapeutics (NASDAQ:CGEM) drew Wall Street's attention last week as William Blair touted the stock after peer-reviewed data for Amgen's (NASDAQ:AMGN) leukemia therapy, Blincyto, which targets CD19 surface antigens on B cells similar to CGEM's lymphoma candidate CLN-978.
Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza
By Colin Kellaher Amgen plans to seek European regulatory approval for the sale of its blockbuster Tepezza treatment for thyroid eye disease. The Thousand Oaks, Calif., biotechnology company on Frid
Amgen Seeks EMA Approval For Teprotumumab In Moderate To Severe Thyroid Eye Disease
Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody an
Express News | Amgen to Submit Teprotumumab Marketing Authorization Application to the European Medicines Agency
Analysis
Price Target
No Data
